Skip to main content
Edwards Lifesciences Logo

The MITRIS RESILIA valve

A legacy of innovation in valve design and tissue technology advancements

Bovine pericardial valves were introduced to improve the outcomes of porcine valves.1–3 

This is because while porcine valves are structurally similar to human valves, they do not account for the higher pressures in the human body.4–7 

For this reason, Edwards Lifesciences has since focused on the development of bovine pericardial valves.

~120

mmHg7

Human systolic left ventricular (LV) pressure

60-100

mmHg5

Porcine systolic LV pressure*

Our commitment to patient well-being continues with our latest mitral innovation: 

The MITRIS RESILIA valve, built on five generations of Edwards mitral tissue valves.

Mitris resilia valve beige background

Key features of the MITRIS RESILIA valve

Edwards Lifesciences developed the MITRIS RESILIA valve, their latest generation valve, by optimising the PERIMOUNT platform. This optimisation fundamentally improved the valve’s design, which in turn enhanced its haemodynamics, durability, and ease of use.8,9

Design

A valve developed specifically for the mitral position
  1. 1
    Valve design: Asymmetrical saddle-shaped sewing cuff to mimic the native mitral annulus
  2. 2
    Valve durability:  RESILIA tissue's† enhanced anti-calcification technology will potentially allow the valve to last longer9
  3. 3
    Valve dimensions: Low-profile valve to minimise risk of left ventricular outflow tract (LVOT) obstruction and LV injury

Explore how the unique design of the MITRIS RESILIA valve compares to porcine valves

Find out more

Haemodynamic performance

Haemodynamically, the MITRIS RESILIA valve outperforms porcine valves8,10

Haemodynamically, pericardial valves provide the best solution to flow problems. The design maximizes use of the flow area, which results in minimal flow resistance

-

Gudbjartsson T, et al.10

Pericardial valve

Pericardial valve

Porcine valve

Porcine valve

Adapted from Gudbarjartsson T, et al. 2003.10

Find out more about the MITRIS RESILIA valve’s haemodynamic performance

Durability

RESILIA tissue,† built with durability in mind. Uncover the evidence supporting RESILIA tissue 

Durability resilia tissue
Find out more

Lifetime management

The MITRIS RESILIA valve – designed for potential future transcatheter interventions

mitris-resilia-slider
mitris-resilia-slider-2

The MITRIS RESILIA valve’s cobalt chromium band was the most visible fluoroscopically compared with porcine valves§ for easy identification of the landing zone for potential future transcatheter interventions.11

Discover how the MITRIS RESILIA valve can impact your patients' lifetime management of mitral valve disease

Find out more

Consider the MITRIS RESILIA valve for your mitral valve replacement patients

Download the leavepiece

*Based on pigs of different weight and age.5

†Clinical data on surgical aortic valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10 years in progress.12

‡12 Yorkshire pigs received comparable valves (27 mm Abbott EpicTM valve [n=4]; 27 mm Medtronic MosaicTM valve [n=4]; 25 mm MITRIS RESILIA valve [n=4]) followed by transcatheter mitral valve replacement ViV with a 26 Edwards Sapien3 valve. Post-ViV, suprasternal transoesophageal echocardiography studies were performed to assess haemodynamic function, followed by gated contrast computed tomography (CT). To ensure comparable anatomical and haemodynamic study conditions, pigs with a >6% anatomical variation were excluded from the study.11

Abbreviations
CT, computed tomography; LV, left ventricular; LVOT, left ventricular outflow tract; ViV, valve-in-valve.

References

  1. Attia RQ & Raja SG. Int J Surg. 2021;94:106121.
  2. Antunes MJ, et al. Eur J Cardiothorac Surg. 2015;47(6):1075–6.
  3. Cosgrove DM, et al. J Thorac Cardiovasc Surg. 1985;89(3):358–68.
  4. Magilligan DJ, et al. J Thorac Cardiovasc Surg. 1985;89(4):499–507.
  5. Lelovas PP, et al. J Am Assoc Lab Anim Sci. 2014;53(5):432–8.
  6. Alexis M, et al. Anat Histol Embryol. 2023;52(6):927–35.
  7. Walker WF & Johnston ID. The Metabolic Basis of Surgical Care, Circulatory Homeostasis (Chapter 5). 1971, Pages 101–124.
  8. Wang DD, et al. J Card Surg. 2021;36(12):4654–62 & supplementary materials.
  9. Flameng W, et al. J Thorac Cardiovasc Surg. 2015;149:340–5.
  10. Gudbjartsson T, et al. Mechanical/Bioprosthetic Mitral Valve Replacement. In: Cohn LH, Edmunds LH Jr, eds. Cardiac Surgery in the Adult. New York: McGraw-Hill, 2003:951986.
  11. Wang DD, et al. Catheter Cardiovasc Interv. 2022;99(3):934–2.
  12. Beaver T, et al. J Thorac Cardiovasc Surg. 2024;168(3):781–91.
Medical device for professional use.

Medical device for professional use.

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, MITRIS, MITRIS RESILIA, PERI, PERIMOUNT, and RESILIA are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

PP--EU-11042 v1.0